BioSpace News Archive

IGC Pharma, Inc. announced a $3 million strategic investment from funds managed by Bradbury Asset Management Limited, a leading asset management firm.

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.

In conjunction with a poster presentation at the United States and Canada Association of Pathologists Annual (USCAP) meeting titled “Current State of Intra-/Interobserver Accuracy and Reproducibility in Tissue Biopsy Grossing and Comparison to an Automated Vision System” – Poster #198, FormaPath is pleased to announce nToto, a new automated tissue visualization system (ATVS) developed in collaboration with Mayo Clinic’s Advanced Diagnostics Laboratory.

VESICA HEALTH, INC., a leading multi-omics liquid biopsy company dedicated to improving the management of hematuria patients and the early detection of bladder cancer had their urine-based biomarker featured in a recent peer-reviewed publication.

argenx SE announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Tuesday, May 7, 2024 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.

Galapagos NV announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation.

OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) today announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer, and Chief Financial Officer, are scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference.

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today highlighted portfolio progress and reported fourth quarter and full year 2023 financial results.

Voyager Therapeutics, Inc. provides for the grant to Dr. Ferguson of a non-qualified stock option and restricted stock units as an inducement material to Dr. Ferguson’s entering into employment with Voyager.

MannKind Corporation announced that Steven B. Binder will retire from his position as Chief Financial Officer, effective April 22, 2024.